Close Menu


Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.

The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.

As part of the deal, Atara will receive $60 million upfront and be eligible for up to $610 million in milestone payments, as well as tiered royalties based on net sales.

The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.

The study, supported by TargetCancer, Foundation Medicine, and Bayer, aims to match 400 patients with rare cancers to personalized treatments based on NGS.

The Phase I trial evaluated the safety and maximum tolerated dose of BAY-1895344 along with objective response rate among patients with DDR deficiencies.

Data presented at ESMO showed that in 175 adults and children with more than 20 kinds of tumors the drug on average can stave off progression for more than three years.

Patients with metastatic solid tumors who are ineligible for surgical resection and who are out of treatment options meet the criteria for testing within the FastTRK program.

Given the rarity of NTRK fusions, the company is also rolling out a free testing program to identify NTRK fusion-positive patients who would benefit from treatment.

In ASCO studies, one PI3K inhibitor showed efficacy in PIK3CA-mutated breast cancer patients progressing on CDK4/6 inhibitors, while the other yielded less encouraging signals.